TXG 10x Genomics Inc

Price (delayed)

$194.43

Market cap

$21.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.26

Enterprise value

$20.78B

Highlights
TXG's equity has surged by 84% year-on-year
The company's gross profit rose by 35% YoY and by 13% QoQ
The company's quick ratio fell by 26% YoY and by 7% QoQ
10x Genomics's debt has increased by 22% YoY and by 15% QoQ

Key stats

What are the main financial stats of TXG
Market
Shares outstanding
109.8M
Market cap
$21.35B
Enterprise value
$20.78B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
28.1
Price to sales (P/S)
63.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.44
Earnings
Revenue
$332.76M
EBIT
-$523.51M
EBITDA
-$502.28M
Free cash flow
-$286.86M
Per share
EPS
-$5.26
Free cash flow per share
-$2.64
Book value per share
$6.92
Revenue per share
$3.06
TBVPS
$8.73
Balance sheet
Total assets
$954.03M
Total liabilities
$201.57M
Debt
$72.5M
Equity
$752.46M
Working capital
$625.17M
Liquidity
Debt to equity
0.1
Current ratio
6.19
Quick ratio
5.82
Net debt/EBITDA
1.14
Margins
EBITDA margin
-150.9%
Gross margin
81.8%
Net margin
-160.2%
Operating margin
-157.6%
Efficiency
Return on assets
-60.8%
Return on equity
-78.8%
Return on invested capital
-306.1%
Return on capital employed
-62.8%
Return on sales
-157.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
-2.18%
1 week
0.48%
1 month
29.29%
1 year
118.85%
YTD
37.31%
QTD
7.42%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$332.76M
Gross profit
$272.34M
Operating income
-$524.47M
Net income
-$533.14M
Gross margin
81.8%
Net margin
-160.2%
The company's gross profit rose by 35% YoY and by 13% QoQ
10x Genomics's revenue has increased by 26% YoY and by 11% from the previous quarter
10x Genomics's net margin has increased by 12% QoQ
10x Genomics's operating margin has increased by 12% QoQ

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
28.1
P/S
63.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.44
TXG's EPS is up by 2% since the previous quarter
TXG's equity has surged by 84% year-on-year
The P/B is 33% above the last 4 quarters average of 21.1
The stock's price to sales (P/S) is 33% more than its last 4 quarters average of 47.6
10x Genomics's revenue has increased by 26% YoY and by 11% from the previous quarter

Efficiency

How efficient is 10x Genomics business performance
The ROE has grown by 14% from the previous quarter
The return on invested capital is up by 13% since the previous quarter
TXG's ROS is up by 12% since the previous quarter
TXG's ROA is up by 11% from the previous quarter

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
TXG's total assets has surged by 56% year-on-year and by 2.7% since the previous quarter
The company's quick ratio fell by 26% YoY and by 7% QoQ
10x Genomics's debt is 90% lower than its equity
TXG's equity has surged by 84% year-on-year
10x Genomics's debt to equity has decreased by 33% YoY but it has increased by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.